Table Ia.
TTI screening results in The Netherlands showing annual averages over the period 2009–2013.
| Agent | N. of tests | N. repeatedly reactive, RR (%) | N. confirmed positive, CP (%) | Positive predictive value, PPV (% = CP*100/RR) |
|---|---|---|---|---|
| HBsAg | 889,297 | 146 (0.02) | 21 (0.0024) | 14.7% |
| Anti-HCVf | 880,942 | 383 (0.04) | 6.2 (0.0007) | 1.6% |
| Anti-HIV | 889,425 | 670 (0.08) | 1.6 (0.0002) | 0.2% |
| Anti-HTLV | 815,934 | 157 (0.02) | 2.5 (0.0003) | 1,6% |
| Syphilis | 889,198 | 111 (0.01) | 15 (0.0017) | 13.5% |
|
| ||||
| Total | - | 1,467 | 47 | 3.2% |
Source: Sanquin Blood Supply, The Netherlands. TTI: transfusion-transmissible infections; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; HIV: human immunodeficiency virus; HTLV: human T-lymphotropic virus.